A Trinity Life Sciences report found that more pharma product launches were successful in 2023 than the year before. Here are ...
Image by Arek Socha from Pixabay November 12, 2024 - By Lorna Fernandes - As fall arrives, so does respiratory syncytial ...
The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...
Regarding hospitalizations among immunocompetent older adults, vaccine effectiveness was 83% for the GSK vaccine and 73% for ...
9 Both RSV and shingles pose serious health risks for older adults ... year to champion healthy ageing in the community," said Raakhi Sippy, General Manager of GSK Singapore. Since its inception in ...
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
Hosted on MSN5d
Year in Review: RSVIn June, the FDA expanded the approval of GSK's RSV vaccine (Arexvy) to include adults ages 50-59 at increased risk of lower ...
Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...
Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.
The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory ...
GlobalData on MSN7d
GSK’s RSV vaccine approved in Canada for adults aged 50 to 59GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease ...
This update in the health sector highlights major developments including DiaSorin's significant profit growth, GSK's RSV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback